Patrick Hwu, President and CEO of the Moffitt Cancer Center, shared a post on LinkedIn:
“How can we help CAR T cells survive longer and fight tumors more effectively?
In this study, Bailey et al. found that deleting the interferon-γ receptor (IFN-γR) in CAR T cells prevents IFN-γ–induced cell death, especially in CD28-based CARs, leading to better and more durable responses.
IFN-γR knockout CAR T cells showed enhanced persistence and memory, and delivered more potent tumor control in both liquid and solid tumor models, even protecting against tumor rechallenge. This approach shows removing IFN-γ signaling can rewire CAR T cells for greater durability and antitumor activity, offering a promising path to improve cell therapy for cancer.”
Title: IFN-γ–resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models
Authors: Stefanie R. Bailey, Hana N. Takei, Giulia Escobar, Michael C. Kann, Amanda A. Bouffard, Tamina Kienka, Valentina M. Supper, Alexander Armstrong, Diego Salas-Benito, Merle K. Phillips, Filippo Birocchi, Sonika Vatsa, Harrison Silva, Irene Scarfò, Marc Wehrli, Korneel Grauwet, Eli P. Darnell, Charlotte E. Graham, Mark B. Leick, Felix Korell, Trisha R. Berger, Marcela V. Maus
Read the full study in Science Magazine.
More posts featuring Patrick Hwu on OncoDaily.
